Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma

Matteo Dell'Olio, Rosario Potito Scalzulli, Grazia Sanpaolo, Michele Nobile, Francesco Saverio Mantuano, Antonio La Sala, Giovanni D'Arena, Eustachio Miraglia, Anna Lucania, Lucia Mastrullo, Cascavilla Nicola

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The incidence of non-Hodgkin lymphomas increases with age. Non-pegylated liposomal formulations of doxorubicin (Myocet®) reduce systemic and cardiac toxicity especially in the elderly, who often have cardiac diseases. We treated 80 patients (mean age 70.9 years) with poor-risk diffuse large B-cell lymphoma with the R-COMP 21 regimen (Myocet® 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg/m 2, prednisone 100 mg/day). In all, 82.5% and 13.7% patients showed complete and partial responses, respectively. Sixty-two of the 80 patients are alive and disease-free (77.5%), while 3/80 are alive with active disease and 15 patients (18.7%) have died (median follow-up: 31 months). The estimated probability of overall survival at 12/24 months from admission was 93.5/87.3%, respectively. There were no therapy-related cardiac events and the ejection fraction improved (from 51.6±6.9% to 54.2±3.9%). Grade 3-4 neutropenia occurred in 22% of patients. We concluded that Myocet® shows both efficacy and tolerability, mainly at the cardiac level.

Original languageEnglish
Pages (from-to)1222-1229
Number of pages8
JournalLeukemia and Lymphoma
Volume52
Issue number7
DOIs
Publication statusPublished - Jul 2011

Fingerprint

B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Doxorubicin
Lymphoma, Large B-Cell, Diffuse
Vincristine
Prednisone
Neutropenia
Cyclophosphamide
Heart Diseases
liposomal doxorubicin
Survival
Incidence

Keywords

  • B-cell lymphoma
  • cardiac toxicity
  • non-pegylated liposomal doxorubicin
  • poor-risk patients

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. / Dell'Olio, Matteo; Potito Scalzulli, Rosario; Sanpaolo, Grazia; Nobile, Michele; Saverio Mantuano, Francesco; La Sala, Antonio; D'Arena, Giovanni; Miraglia, Eustachio; Lucania, Anna; Mastrullo, Lucia; Nicola, Cascavilla.

In: Leukemia and Lymphoma, Vol. 52, No. 7, 07.2011, p. 1222-1229.

Research output: Contribution to journalArticle

Dell'Olio, M, Potito Scalzulli, R, Sanpaolo, G, Nobile, M, Saverio Mantuano, F, La Sala, A, D'Arena, G, Miraglia, E, Lucania, A, Mastrullo, L & Nicola, C 2011, 'Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma', Leukemia and Lymphoma, vol. 52, no. 7, pp. 1222-1229. https://doi.org/10.3109/10428194.2011.572321
Dell'Olio, Matteo ; Potito Scalzulli, Rosario ; Sanpaolo, Grazia ; Nobile, Michele ; Saverio Mantuano, Francesco ; La Sala, Antonio ; D'Arena, Giovanni ; Miraglia, Eustachio ; Lucania, Anna ; Mastrullo, Lucia ; Nicola, Cascavilla. / Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. In: Leukemia and Lymphoma. 2011 ; Vol. 52, No. 7. pp. 1222-1229.
@article{b63dcf2cbb6a46bcbeebed2ba4968486,
title = "Non-pegylated liposomal doxorubicin (Myocet{\circledR}) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma",
abstract = "The incidence of non-Hodgkin lymphomas increases with age. Non-pegylated liposomal formulations of doxorubicin (Myocet{\circledR}) reduce systemic and cardiac toxicity especially in the elderly, who often have cardiac diseases. We treated 80 patients (mean age 70.9 years) with poor-risk diffuse large B-cell lymphoma with the R-COMP 21 regimen (Myocet{\circledR} 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg/m 2, prednisone 100 mg/day). In all, 82.5{\%} and 13.7{\%} patients showed complete and partial responses, respectively. Sixty-two of the 80 patients are alive and disease-free (77.5{\%}), while 3/80 are alive with active disease and 15 patients (18.7{\%}) have died (median follow-up: 31 months). The estimated probability of overall survival at 12/24 months from admission was 93.5/87.3{\%}, respectively. There were no therapy-related cardiac events and the ejection fraction improved (from 51.6±6.9{\%} to 54.2±3.9{\%}). Grade 3-4 neutropenia occurred in 22{\%} of patients. We concluded that Myocet{\circledR} shows both efficacy and tolerability, mainly at the cardiac level.",
keywords = "B-cell lymphoma, cardiac toxicity, non-pegylated liposomal doxorubicin, poor-risk patients",
author = "Matteo Dell'Olio and {Potito Scalzulli}, Rosario and Grazia Sanpaolo and Michele Nobile and {Saverio Mantuano}, Francesco and {La Sala}, Antonio and Giovanni D'Arena and Eustachio Miraglia and Anna Lucania and Lucia Mastrullo and Cascavilla Nicola",
year = "2011",
month = "7",
doi = "10.3109/10428194.2011.572321",
language = "English",
volume = "52",
pages = "1222--1229",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma

AU - Dell'Olio, Matteo

AU - Potito Scalzulli, Rosario

AU - Sanpaolo, Grazia

AU - Nobile, Michele

AU - Saverio Mantuano, Francesco

AU - La Sala, Antonio

AU - D'Arena, Giovanni

AU - Miraglia, Eustachio

AU - Lucania, Anna

AU - Mastrullo, Lucia

AU - Nicola, Cascavilla

PY - 2011/7

Y1 - 2011/7

N2 - The incidence of non-Hodgkin lymphomas increases with age. Non-pegylated liposomal formulations of doxorubicin (Myocet®) reduce systemic and cardiac toxicity especially in the elderly, who often have cardiac diseases. We treated 80 patients (mean age 70.9 years) with poor-risk diffuse large B-cell lymphoma with the R-COMP 21 regimen (Myocet® 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg/m 2, prednisone 100 mg/day). In all, 82.5% and 13.7% patients showed complete and partial responses, respectively. Sixty-two of the 80 patients are alive and disease-free (77.5%), while 3/80 are alive with active disease and 15 patients (18.7%) have died (median follow-up: 31 months). The estimated probability of overall survival at 12/24 months from admission was 93.5/87.3%, respectively. There were no therapy-related cardiac events and the ejection fraction improved (from 51.6±6.9% to 54.2±3.9%). Grade 3-4 neutropenia occurred in 22% of patients. We concluded that Myocet® shows both efficacy and tolerability, mainly at the cardiac level.

AB - The incidence of non-Hodgkin lymphomas increases with age. Non-pegylated liposomal formulations of doxorubicin (Myocet®) reduce systemic and cardiac toxicity especially in the elderly, who often have cardiac diseases. We treated 80 patients (mean age 70.9 years) with poor-risk diffuse large B-cell lymphoma with the R-COMP 21 regimen (Myocet® 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg/m 2, prednisone 100 mg/day). In all, 82.5% and 13.7% patients showed complete and partial responses, respectively. Sixty-two of the 80 patients are alive and disease-free (77.5%), while 3/80 are alive with active disease and 15 patients (18.7%) have died (median follow-up: 31 months). The estimated probability of overall survival at 12/24 months from admission was 93.5/87.3%, respectively. There were no therapy-related cardiac events and the ejection fraction improved (from 51.6±6.9% to 54.2±3.9%). Grade 3-4 neutropenia occurred in 22% of patients. We concluded that Myocet® shows both efficacy and tolerability, mainly at the cardiac level.

KW - B-cell lymphoma

KW - cardiac toxicity

KW - non-pegylated liposomal doxorubicin

KW - poor-risk patients

UR - http://www.scopus.com/inward/record.url?scp=79959582374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959582374&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.572321

DO - 10.3109/10428194.2011.572321

M3 - Article

VL - 52

SP - 1222

EP - 1229

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -